- Home
- RIVN vs INCY Comparison
RIVN vs INCY Comparison
Compare RIVN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIVN | INCY |
|---|---|---|
| Founded | 2009 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8B | 17.0B |
| IPO Year | 2021 | 1993 |
Fundamental Metrics
Financial Performance| Metric | RIVN | INCY |
|---|---|---|
| Price | $17.25 | $101.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 20 |
| Target Price | $14.79 | ★ $90.71 |
| AVG Volume (30 Days) | ★ 62.3M | 2.1M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3878.02 |
| EPS | N/A | ★ 5.90 |
| Revenue | ★ $5,835,000,000.00 | $4,813,105,000.00 |
| Revenue This Year | $10.72 | $19.33 |
| Revenue Next Year | $31.78 | $10.47 |
| P/E Ratio | ★ N/A | $17.17 |
| Revenue Growth | ★ 28.21 | 18.09 |
| 52 Week Low | $10.36 | $53.56 |
| 52 Week High | $18.13 | $109.28 |
Technical Indicators
Market Signals| Indicator | RIVN | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 65.85 | 52.40 |
| Support Level | $13.95 | $100.30 |
| Resistance Level | $17.79 | $107.61 |
| Average True Range (ATR) | 0.93 | 2.83 |
| MACD | 0.15 | -0.89 |
| Stochastic Oscillator | 88.02 | 14.60 |
Price Performance
Historical ComparisonAbout RIVN Rivian Automotive Inc.
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.